Azcuris

Market position

Azcuris is an early-stage, discovery-phase Korean biotech competing in the immunology and respiratory therapeutics field, where injectable antibody drugs dominate. Its stated target market is defined by the dominance of Dupixent (dupilumab), a Sanofi and Regeneron injectable antibody with $17.8 billion in 2025 sales across asthma and atopic dermatitis, and by existing oral JAK inhibitors for atopic dermatitis (Rinvoq, Cibinqo) that carry boxed warnings for serious infections, blood clots and malignancy. Azcuris frames the unmet gap as the absence of an oral drug with a safety profile comparable to Dupixent in either indication. Validation to date comes chiefly from its option-based research collaboration with AstraZeneca; the same AstraZeneca event surfaced a parallel deal with Galux, an AI protein-design startup.

The company differentiates on modality and route of administration: small molecules taken orally rather than injected antibodies, which company scientists argue lowers cost and administration burden and could allow use earlier in the disease course, including in milder asthma, thereby addressing a larger patient population than biologics reserved for severe, uncontrolled disease. Its technical differentiator is a fragment-based platform built to drug protein-protein interactions.

Technology

Azcuris's discovery engine combines fragment-based and structure-based drug discovery aimed at protein-protein interactions, a target class historically difficult to address with small molecules. Named platform components include CytoFBDD, CytoStructure, CytoNMR and CytoAssay. The company applies this suite to identify and block key protein-protein interactions that initiate immune responses, generating orally administered small-molecule candidates; its lead effort targets salt-inducible kinase (SIK).

Go-to-market

Azcuris pursues partnerships with global pharmaceutical companies as its principal route to development and commercialization, using government-supported business development forums such as the KHIDI-AstraZeneca Project NOVA Global Connect event at BIO USA to reach potential partners. Its website also references investor relations activity and a promotional shoot at J-LABS Korea. Development and regulatory strategy in Korea is tied to undisclosed terms of the AstraZeneca agreement.

Ultimately patients with immune-mediated, allergic and inflammatory diseases, initially atopic dermatitis and asthma. Its direct counterparties are pharmaceutical companies and research organizations that license or co-develop programs built on its discovery platform.

Geography

Headquartered in Sejong, South Korea, with partnering and business development activity conducted internationally, including at industry events in San Diego, California.

History

The company was established in 2018 in Sejong, South Korea. It raised a 4 billion won Series A in 2020 and a 1 billion won bridge round in 2021, then went roughly five years without another institutional round. In April 2026 it closed a Series B of about 5 billion won backed by Atinum Investment and other venture firms. On June 19, 2026 it signed its first partnership with a global pharmaceutical company, a research collaboration with AstraZeneca, announced three days later at the BIO International Convention in San Diego during the Project NOVA Global Connect event run jointly by AstraZeneca and the Korea Health Industry Development Institute (KHIDI).

Risks & controversies

The lead program is at the discovery stage, ahead of preclinical development, and the AstraZeneca arrangement is an option to license rather than an executed license, so whether it is exercised and on what terms depends on research outcomes; financial terms were not disclosed. According to investor Atinum Investment, AstraZeneca requested that its logo be removed from certain announcement materials and that related website content be taken down. AstraZeneca has not publicly identified the molecular target. Reported financials show operating and net losses in 2021 and 2022 with no recorded revenue through 2025, and the company went roughly five years between institutional financings.